For example, miR‐133a can inhibit cell proliferation and invasiveness through directly suppressing the expressions of insulin‐like growth factor 1 receptor, TGF‐beta receptor type‐1, EGFR in non‐small cell lung cancer 21, and breast cancer 7. This evidence concerns the gene EGFR and breast carcinoma.